newsfilter
← Latest News
GlobeNewswire·

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

- Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™